Cargando…
CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta‐analysis
BACKGROUND: CGRP monoclonal antibody (mAb) is a promising preventive treatment for episodic migraine and has been approved by US FDA recently. But the treatments for chronic migraine are rare. Therefore, we performed meta‐analysis to assess the efficacy and safety of CGRP mAbs in preventing chronic...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379644/ https://www.ncbi.nlm.nih.gov/pubmed/30656853 http://dx.doi.org/10.1002/brb3.1215 |